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OBJECTIVEdMacronutrient “preloads” can reduce postprandial glycemia by slowing gastric
emptying and stimulating glucagon-like peptide-1 (GLP-1) secretion. An ideal preload would
entail minimal additional energy intake and might be optimized by concurrent inhibition of
dipeptidyl peptidase-4 (DPP-4). We evaluated the effects of a low-energy D-xylose preload, with
or without sitagliptin, on gastric emptying, plasma intact GLP-1 concentrations, and postpran-
dial glycemia in type 2 diabetes.
RESEARCH DESIGN ANDMETHODSdTwelve type 2 diabetic patients were studied
on four occasions each. After 100 mg sitagliptin (S) or placebo (P) and an overnight fast, patients
consumed a preload drink containing either 50 g D-xylose (X) or 80 mg sucralose (control [C]),
followed after 40min by amashed potato meal labeled with 13C-octanoate. Blood was sampled at
intervals. Gastric emptying was determined.
RESULTSdBoth peak blood glucose and the amplitude of glycemic excursion were lower after
PX and SC than PC (P, 0.01 for each) and were lowest after SX (P, 0.05 for each), while overall
blood glucose was lower after SX than PC (P, 0.05). The postprandial insulin-to-glucose ratio
was attenuated (P , 0.05) and gastric emptying was slower (P , 0.01) after D-xylose, without
any effect of sitagliptin. Plasma GLP-1 concentrations were higher after D-xylose than control
only before the meal (P , 0.05) but were sustained postprandially when combined with sita-
gliptin (P , 0.05).
CONCLUSIONSdIn type 2 diabetes, acute administration of a D-xylose preload reduces
postprandial glycemia and enhances the effect of a DPP-4 inhibitor.
Diabetes Care 36:1913–1918, 2013
Therapeutic strategies directed at re-ducing postprandial glycemia are offundamental importance in the
management of type 2 diabetes (1). For
patients with mild-to-moderate hypergly-
cemia, postprandial blood glucose is a
better predictor of HbA1c than fasting
blood glucose (2).
Both gastric emptying and the action
of the incretin hormones glucagon-like
peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are ma-
jor determinants of postprandial glucose
excursions (3). Gastric emptying deter-
mines the rate of nutrient delivery to the
small intestine, accounting for approxi-
mately one-third of the variation in the
initial rise in glycemia after oral glucose
in both healthy subjects (4) and those
with type 2 diabetes (5). GLP-1 and GIP,
released predominantly from the distal
and proximal gut, respectively, are the
known mediators of the incretin effect,
whereby much more insulin is stimulated
by enteral compared with intravenous
glucose (6). In type 2 diabetes, the incre-
tin effect is impaired (7), related at least
partly to a diminished insulinotropic ef-
fect of GIP, while that of GLP-1 is pre-
served (8). In addition, GLP-1 slows
gastric emptying (9), suppresses glucagon
secretion (10), and reduces energy intake
(11). Therefore, incretin-based therapies
for diabetes have hitherto focused on
GLP-1.
One promising strategy to stimulate
endogenous GLP-1 is the “preload” con-
cept, which involves administration of a
small load of macronutrient at a ﬁxed in-
terval before ameal so that the presence of
nutrients in the small intestine induces
the release of gut peptides, including
GLP-1, to slow gastric emptying and im-
prove the glycemic response to the sub-
sequent meal. Fat (12) and protein (13)
preloads achieve these goals but entail ad-
ditional energy intake. We recently dem-
onstrated in healthy subjects the potential
for poorly absorbed sweeteners, which
yield little energy, to stimulate GLP-1 se-
cretion and slow gastric emptying (14).
D-Xylose is a pentose sugar, which is
incompletely absorbed by passive diffu-
sion in human duodenum and jejunum
(15), with the remainder delivered to
the ileum and the colon, where bacterial
fermentation occurs, producing hydro-
gen that can be detected in the breath
(16). We recently showed that oral con-
sumption of D-xylose stimulates GLP-1
secretion to a greater and more sustained
degree than glucose in healthy older sub-
jects (17), consistent with the principle
that the length and region of small intes-
tine exposed to carbohydrate are impor-
tant determinants of GLP-1 release (18).
D-Xylose also slowed gastric emptying
compared with water, with efﬁcacy simi-
lar to that of the glucose load (17).
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IntactGLP-1 is short-lived in the circu-
lation largely because of rapid degradation
by the enzyme dipeptidyl peptidase-4
(DPP-4) (19), and orally administered
DPP-4 inhibitors, such as sitagliptin, in-
crease postprandial plasma concentra-
tions of intact GLP-1 (20). However, the
concept of stimulating endogenous GLP-1
with enteral nutrients and then opti-
mizing its action with a DPP-4 inhibitor
has received little attention. Moreover,
little consideration has been given as to
whether the composition of the diet in-
ﬂuences the efﬁcacy of DPP-4 inhibition
to lower postprandial blood glucose.
The current study was designed to
determine, in patients with type 2 di-
abetes, whether a D-xylose preload would
slow gastric emptying, stimulate GLP-1
secretion, and improve postprandial
glycemia and whether these effects could
be enhanced by DPP-4 inhibition.
RESEARCH DESIGN AND
METHODSdTwelve patients with
type 2 diabetes (9 males and 3 females),
managed by diet alone, were studied after
they had provided written informed con-
sent. The mean 6 SE age was 66.26 1.4
years, BMI 28.9 6 1.0 kg/m2, HbA1c
6.6 6 0.2% (48.9 6 2.5 mmol/mol),
and duration of known diabetes 4.9 6
1.1 years. None had signiﬁcant comor-
bidities, were smokers, or were taking
any medication known to affect gastroin-
testinal function. The protocol was ap-
proved by the human research ethics
committee of the Royal Adelaide Hospital
and was conducted in accordance with
the principles of the Declaration of Hel-
sinki as revised in 2000.
Each subject was studied on four
occasions, separated by at least 3 days,
in randomized double-blind fashion. On
the evening before each study day
(;1900 h), each subject consumed a
standardized evening meal (McCain’s fro-
zen beef lasagna, 2,170 kJ; McCain Foods
Proprietary,Victoria, Australia). At;2200h,
subjects took a tablet of either 100 mg
sitagliptin (Januvia; Merck Sharp &
Dohme) or matching placebo, and com-
pliance was reinforced with a reminder
phone call that evening.
Subjects then fasted until the follow-
ing morning, when they attended the
laboratory at ;0800 h and were seated
comfortably for the duration of the study.
An intravenous cannula was inserted into
an antecubital vein for repeated blood
sampling. On each study day, between
t = 240 and 238 min, they consumed a
200-mL preload drink containing either
50 g D-xylose or 80 mg sucralose (a con-
trol of equivalent sweetness, which we
have shown not to stimulate GLP-1 secre-
tion or slow gastric emptying in healthy
humans [21,22]), so that the four treat-
ments were sitagliptin plus D-xylose (SX),
sitagliptin plus control (SC), placebo plus
D-xylose (PX), and placebo plus control
(PC). Forty minutes later (between t =
0 and 5 min), they ate a solid meal con-
sisting of 65 g powdered potato (Deb
Instant Mashed Potato; Continental, Ep-
ping, Australia) and 20 g glucose, recon-
stituted with 200mLwater and 1 egg yolk
containing 100 mL 13C-octanoic acid.
Breath samples were collected immedi-
ately before and every 5 min after meal
ingestion in the ﬁrst hour and every 15
min for a further 3 h for the measurement
of gastric emptying. Venous blood sam-
ples and additional breath samples before
the preload drink (at t =240 min) and at
t = 220, 0, 15, 30, 60, 90, 120, and 240
min were taken for the measurements of
blood glucose, insulin, intact GLP-1, and
breath hydrogen.
Blood samples for insulin were col-
lected in serum tubes. For the measure-
ment of intact GLP-1, venous blood was
collected into ice-chilled EDTA tubes con-
taining DPP-4 inhibitor (DPP4-010; Linco
Research, St. Charles, MO) (10 mL/mL
blood). Samples were mixed six times by
gentle inversion and stored on ice before
centrifugation at 3,200 rpm for 15 min at
48C within 15 min of collection. Serum
and plasma were separated and stored
at –708C for subsequent analysis.
Blood glucose, serum insulin, and
intact GLP-1
Blood glucose concentrations were mea-
sured immediately using a glucometer
(Medisense Precision QID; Abbott Labo-
ratories, Bedford, MA). The accuracy of
the method has been validated against the
hexokinase technique (4).
Serum insulin was measured by
ELISA immunoassay (cat. no. 10-1113;
Mercodia, Uppsala, Sweden). The sensi-
tivity of the assay was 1.0 mU/L and the
coefﬁcient of variation was 2.1% within
assays and 6.6% between assays.
Plasma intact GLP-1 wasmeasured by
radioimmunoassay using a commercially
available kit (GLP1A-35HK; Millipore,
Billerica, MA), which allows quantiﬁca-
tion of biologically active forms of GLP-1
(i.e., 7-36 amide and 7-37) in plasma and
other biological media. The sensitivity
was 3 pmol/L, and intra- and interassay
coefﬁcients of variation were 3.4 and
9.1%, respectively.
Gastric emptying
13CO2 concentrations in breath samples
were measured by an isotope ratio mass
spectrometer (ABCA 2020; Europa Scien-
tiﬁc, Crewe, U.K.) with an online gas
chromatographic puriﬁcation system.
The half-emptying time (T50) was calcu-
lated, using the formula described by
Ghoos et al. (23). This method has been
validated against scintigraphy for the
measurement of gastric emptying (24).
Breath hydrogen
Hydrogen concentrations in breath sam-
ples were measured using Quintron
MicroLyzer SC (Quintron Instrument,
Milwaukee, WI) and were corrected for
CO2 levels (25).
Statistical analysis
The incremental areas under the curve
(iAUCs) were calculated using the trape-
zoidal rule (26) for blood glucose, serum
insulin, plasma intact GLP-1, and breath
hydrogen and analyzed using one-factor
repeated-measures ANOVA. These varia-
bles were also assessed by repeated-
measures ANOVA, with treatment and
time as factors. The amplitude of glycemic
excursion (AGE) (postprandial glycemic
peak minus the nadir) and J index [ J =
0.324 3 (mean blood glucose + SD)2]
were calculated as measures of glycemic
variability, as previously described (27),
and these together with gastric emptying
(T50) were compared using one-factor
ANOVA. Post hoc comparisons, adjusted
for multiple comparisons by Bonferroni-
Holm correction, were performed if
ANOVAs showed signiﬁcant effects. Rela-
tionships between variables were assessed
using linear regression analysis. All anal-
yses were performed with SPSS Statistics
(version 19.0; IBM, Armonk, NY). Data
are presented as means 6 SE; P , 0.05
was considered statistically signiﬁcant.
RESULTSdAll subjects tolerated the
study well. Three subjects reported mild
transient loose stools after completion of
the study on the D-xylose days.
Blood glucose concentrations
Fasting blood glucose concentrations did
not differ between the four study days (PC
7.46 0.3 mmol/L, PX 7.56 0.3 mmol/L,
SC 7.1 6 0.3 mmol/L, and SX 7.5 6 0.4
mmol/L). Before the meal, blood glucose
concentrations increased slightly when
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the D-xylose preload was given (i.e., PX
and SX) in contrast to the control days,
so that the iAUC (240 to 0 min) was
greater for PX and SX than for PC and
SC (P , 0.05 for each) (Table 1). After
the meal, blood glucose concentrations
increased on each day before returning
to baseline. The postprandial glycemic
peak, AGE, and J index were all lower
after PX and SC than PC (P , 0.01 for
each) and were lowest after SX (P, 0.05
for each) (Table 1). There was a signiﬁ-
cant treatment effect on the overall iAUC
for blood glucose (P = 0.008) (Table 1),
such that blood glucose was lower after
SX compared with PC (P , 0.05)
(Fig. 1A).
Serum insulin
Fasting serum insulin concentrations did
not differ between the four study days.
Before the meal, insulin concentrations
increased slightly when D-xylose was
given (i.e., PX and SX) in contrast to the
control days, so that the iAUC (240 to
0 min) was greater for PX and SX than
for PC and SC (P, 0.05 for each) (Table
1). After the meal, serum insulin con-
centrations increased on each day, but
D-xylose and sitagliptin alone and in
combination resulted in a lower post-
prandial serum insulin than PC (P =
0.000 for treatment 3 time interaction,
with signiﬁcant differences at t = 30, 60,
and 90 min for PX vs. PC and SX vs. PC;
t = 90min for SC vs. PC; and t = 30min for
SX vs. SC [P, 0.05 for each]). There was
also a signiﬁcant treatment effect on the
overall iAUC for serum insulin (P = 0.009)
(Table 1), such that insulin concentra-
tions were lower after SX than PC (P ,
0.05) (Fig. 1B).
Before the meal, the insulin-to-
glucose ratio (Fig. 1C) remained unchanged
after both D-xylose and control preloads,
but the ratio increased after the meal and
was lower from t = 30 to 90 min after the
D-xylose preload compared with control
(P = 0.000 for a treatment3 time interac-
tion: PX vs. PC and SX vs. SC [P, 0.05 for
each]) without any effect of sitagliptin.
Plasma intact GLP-1
Fasting plasma intact GLP-1 concentra-
tions did not differ between the four study
days. Before the meal, GLP-1 concentra-
tions increased when the D-xylose preload
was given, so that the iAUC (240 to 0)
was greater for SX than for PC and SC (P
, 0.05 for each) (Table 1), although the
difference between PX and PC was not
signiﬁcant. After the meal, intact GLP-1
increased on the control days, but the
combination of the D-xylose preload
with sitagliptin resulted inmore sustained
elevation of plasma intact GLP-1 than on
the other days (P = 0.000 for a treatment3
time interaction, with signiﬁcant differ-
ences at t = 15, 60, 90, and 120 min for
SX vs. PC and during t = 30–120 for SX vs.
PX [P , 0.05 for each]). There was also a
treatment effect on the overall iAUC for
plasma intact GLP-1 (P = 0.003) (Table
1), such that GLP-1 was greatest after SX
(SX vs. PC, PX, and SC, P, 0.05 for each)
(Fig. 1D).
Breath hydrogen production
Fasting breath hydrogen approximated
0 ppm and did not differ between the four
study days. After the D-xylose drink,
breath hydrogen increased slightly before
the meal (t = 240 to 0 min) and contin-
ued to rise to a plateau afterward, while it
remained unchanged after the control
preload and was unaffected by sitagliptin
(P = 0.000 for a treatment 3 time inter-
action) (Fig. 2).
Gastric emptying
There was a treatment effect for gastric
emptying (P = 0.000), such that the half-
emptying time was greater after D-xylose
than control (T50 for PX 238.2 6 26.4
min and SX 256.9 6 23.1 min vs. PC
152.3 6 6.0 min and SC166.3 6 11.0
min [P , 0.01 for each]) without any ef-
fect of sitagliptin (Fig. 3).
Relationships between blood glucose
and gastric emptying, plasma intact
GLP-1, and breath hydrogen
production
When data from the four study visits were
pooled, the magnitude of the postpran-
dial rise in blood glucose from baseline at
t = 30, 60, and 90 min was inversely re-
lated to the T50 (P, 0.01 for each) and at
t = 240min directly related to the T50 (P =
0.001).
Given that plasma intact GLP-1
would be more sensitive as a measure of
GLP-1 secretion when DPP-4 was inhib-
ited, data from the SX day alone were ex-
amined for a relationship between breath
hydrogen production and GLP-1 secre-
tion. Intact GLP-1 concentrations were
found to be related directly to breath
hydrogen production (for iAUC240 to 0,
r = 0.72, P = 0.009; for iAUC240 to 240, r =
0.74, P = 0.006).
CONCLUSIONSdThe main observa-
tions made in this study of patients with
type 2 diabetes managed by diet were that
1) consumption of the low-energy pentose
D-xylose in advance of a high-carbohydrate
meal attenuates the postprandial glycemic
excursion in association with stimulation
of GLP-1 secretion before the meal and
slowing of gastric emptying, 2) a single
dose of the DPP-4 inhibitor sitagliptin
increases postprandial intact GLP-1
Table 1dPostprandial glycemic peak, J index, AGE, iAUC for blood glucose, serum insulin, and GLP-1 in response to a carbohydrate meal
after a preload of either D-xylose or sucralose (control) with or without 100 mg sitagliptin (n = 12)
PC PX SC SX P
Glycemic peak (mmol/L) 14.8 6 0.6 13.3 6 0.6a 13.2 6 0.6b 12.3 6 0.6cde 0.000
J index (mmol2/L2) 54.7 6 4.5 46.7 6 3.8a 44.1 6 3.9b 39.2 6 3.4cde 0.000
AGE (mmol/L) 8.7 6 0.5 6.5 6 0.5a 7.3 6 0.5b 5.5 6 0.5cde 0.000
Glucose iAUC240 to 0 (mmol/L 3 min) 3.8 6 1.4 15.3 6 4.5
a 3.1 6 2.0 12.2 6 3.8ce 0.010
Glucose iAUC240 to 240 (mmol/L 3 min) 872.6 6 101.4 797.1 6 68.1 717.5 6 103.8 630.7 6 86.8
c 0.008
Insulin iAUC240 to 0 (mU/L 3 min) 11.3 6 5.0 54.7 6 10.8
a 17.3 6 6.2 53.7 6 17.9ce 0.006
Insulin iAUC240 to 240 (mU/L 3 min) 6,715.2 6 1,701.8 5,343.4 6 1,203.0 5,754.1 6 1,230.0 3,972.9 6 563.2
c 0.009
Intact GLP-1 iAUC240 to 0 (pmol/L 3 min) 14.3 6 6.7 52.2 6 20.5 8.3 6 3.3 86.8 6 28.9
ce 0.004
Intact GLP-1 iAUC240 to 240 (pmol/L 3 min) 135.8 6 36.7 125.0 6 39.1 130.5 6 38.5 492.1 6 161.4
cde 0.003
Data are means6 SEM. One-factor repeated-measures ANOVAwas used to determine statistical difference. Post hoc comparisons were adjusted by Bonferroni-Holm
correction. aP , 0.05, PX vs. PC; bP , 0.05, SC vs. PC; cP , 0.05, SX vs. PC; dP , 0.05, SX vs. PX; eP , 0.05, SX vs. SC.
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concentrations and reduces postprandial
glycemia without slowing gastric empty-
ing or stimulating postprandial insulin
secretion, and 3) the combination of a
D-xylose preload with sitagliptin reduces
the postprandial glycemic excursion more
than either treatment alone. Themagnitude
of the reduction in postprandial blood
glucose achieved by the combination
of D-xylose preload and sitagliptin in
our group of patients with well-con-
trolled type 2 diabetes was substantial
(i.e., reduction in peak blood glucose of
;2.5 mmol/L), and moreover, there was a
marked reduction in indices of glycemic
variability; the latter is associated with oxi-
dative stress and may independently in-
crease cardiovascular risk (27).
We chose D-xylose as the preload,
since it is incompletely absorbed and
poorly metabolized (16) and, accord-
ingly, additional energy intake is mini-
mized in contrast to preloads such as fat
(12) and protein (13). Consistent with
our previous report in healthy older sub-
jects (17), ingestion of D-xylose resulted
in a modest increase in blood glucose and
serum insulin, possibly as a result of en-
hanced gluconeogenesis. Sucralose was
selected as a sweet-tasting negative con-
trol, since we have shown that this artiﬁ-
cial sweetener when given acutely has no
effect on either the secretion of GLP-1 or
gastric emptying (21,22), and indeed in
the current study, there was no increase in
intact GLP-1 before the meal on the days
when sucralose was given. The osmolarity
of the preloads could not readily be
matched without changing the taste and
this may have contributed to the effect of
the D-xylose preload on gastric emptying
(28) but is unlikely to account for differ-
ences in GLP-1 secretion (22).
As expected, D-xylose was associated
with stimulation of GLP-1 in advance of
the meal. It has been postulated that in-
testinal fermentation to form free fatty
acids represents an important mechanism
for the stimulation of GLP-1 release (29);
the latter could be indirectly quantiﬁed by
resultant hydrogen production in breath
samples (16). Our demonstration of a re-
lationship between GLP-1 concentrations
and hydrogen production is consistent
with this concept. However, the fact that
GLP-1 concentrations began to increase
within 20 min of D-xylose ingestion sug-
gests that other mechanisms, involving,
for example, the passage of D-xylose
through the monosaccharide transporters
GLUT2 and GLUT3 (30), are likely in-
volved. It may appear surprising that
plasma intact GLP-1 levels after the potato
meal did not differ between the D-xylose
and control preload study days, when
sitagliptin was not given. However, the
magnitude of GLP-1 secretion is depen-
dent on the rate (31) and load (32) of nu-
trient entry to the small intestine, so that
the slowing of gastric emptying induced
by the D-xylose preload may well have at-
tenuated the component of the postpran-
dial GLP-1 response attributable to the
meal.
We observed that the magnitude of
the initial postprandial glycemic excur-
sion was inversely related to the gastric
half-emptying time, consistent with evi-
dence that the rate of gastric emptying
is a major determinant of postprandial
glycemia (4,5). In the absence of
sitagliptin, the reduction in postprandial
glycemia by D-xylose is probably attrib-
utable mainly to the slowing of gastric
emptying, since postprandial intact GLP-1
concentrations were no greater than on
the control day. The observed decrease
in postprandial insulin concentrations af-
ter D-xylose in contrast to control, partic-
ularly when corrected for differences in
blood glucose (i.e., the insulin-to-glucose
ratio), is consistent with what would be
expected when gastric emptying of the
potato meal is slower (12).
The slowing of gastric emptying after
the D-xylose preload was associated with
stimulation of GLP-1 in advance of the
meal, although postprandial intact GLP-1
concentrations were not increased in the
absence of sitagliptin. Since endogenous
Figure 1dEffects of D-xylose or sucralose (control) with or without sitagliptin on blood glucose
(A), serum insulin (B), insulin-to-glucose ratio (C), and plasma intact GLP-1 (D) in response to
a carbohydrate meal (n = 12). The four treatments were SX, SC, PX, and PC. Repeated-measures
ANOVA was used to determine statistical difference. Post hoc comparisons were adjusted by
Bonferroni-Holm correction. P = 0.000 for each treatment3 time interaction; *P, 0.05, PX vs.
PC; #P, 0.05, SC vs. PC;aP, 0.05, SX vs. PC; dP, 0.05, SX vs. PX; «P, 0.05, SX vs. SC. Data
are means 6 SEM.
Figure 2dEffects of D-xylose or sucralose
(control) with or without sitagliptin on breath
hydrogen production in response to a carbo-
hydrate meal (n = 12). The four treatments
were SX (-), SC (C), PX (,), and PC (○).
Repeated-measures ANOVA was used to de-
termine statistical difference. *P = 0.000, PX
vs. PC and SC; #P = 0.000, SX vs. PC and SC.
Data are means 6 SEM.
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GLP-1 is known to slow gastric emptying
(9), the elevated GLP-1 may have contrib-
uted to the slower gastric emptying after
D-xylose, at least during the initial phase.
Nevertheless, the combination with
sitagliptin, which increased plasma con-
centrations of intact GLP-1, had no ad-
ditional effect on the rate of gastric
emptyingda ﬁnding that is consistent
with our recent report of the lack of effect
of 2-day dosing with sitagliptin on gastric
emptying (33). This is likely to be because
gastric emptying is modulated by multiple
mechanisms. For example, acute hyper-
glycemia, even within the physiological
range, is known to slow gastric emptying
(34), and sitagliptin, particularly when
combined with D-xylose, potently de-
creased postprandial glycemia. Moreover,
peptide YY (PYY), which is cosecreted
with GLP-1 from enteroendocrone L cells,
has the capacity to slow gastric emptying.
PYY 1-36 and 3-36 are the predominant
biologically active forms in the circulation;
the latter is formed from degradation of
PYY 1-36 by DPP-4 and is reportedly
more potent at retarding emptying (35).
Therefore, DPP-4 inhibition might, to
some extent, blunt PYY- mediated slowing
of gastric emptying.
In contrast, addition of sitagliptin did
not affect gastric emptying but was as-
sociated with lowering of postprandial
glycemia. Despite the fact that plasma
intact GLP-1 concentrations were in-
creased after sitagliptin, particularly
when given in combinationwith D-xylose,
the insulin response to the meal did
not increase in parallel. This is partly
accounted for by the fact that the
insulinotropic effect of GLP-1 is glucose
dependent (36), but there is also evidence
that mechanisms other than insulin secre-
tion are likely to be important in mediat-
ing the glucose-lowering effect of GLP-1;
the latter include suppression of both glu-
cagon secretion and endogenous glucose
production (37,38) and enhancement of
peripheral glucose uptake (39).
It is noteworthy that there has been
little consideration of how dietary intake
interacts with the actions of DPP-4 inhib-
itors. The current study is therefore novel
in demonstrating how consumption of a
speciﬁc nutrient can improve the efﬁcacy
of a DPP-4 inhibitor for reducing post-
prandial glycemia. Although the number
of subjects studied was relatively small,
the observed effects were consistent be-
tween subjects and were in keeping with
previous observations relating to the
slowing of gastric emptying by D-xylose
(17) and glucose lowering by sitagliptin
(20). Our study represents an acute inter-
vention in a relatively well-controlled
group of patients with type 2 diabetes
managed by diet alone. In view of the pos-
itive outcomes, it would be of particular
interest to investigate this approach in
type 2 diabetic patients takingmetformin,
given the synergistic effect of DPP-4 in-
hibitors with metformin for increasing in-
tact GLP-1 and improving glycemia (40),
and to extend our observations to larger
and more diverse groups of type 2 dia-
betic patients over a longer duration.
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